1. health and fitness
2. disease
3. cancer

Introduction to Endoscopic Ultrasound Fine
Needle Aspiration (EUS-FNA) Sample Preparation
Sampling Techniques, Cytology vs Histology & Case Studies
Presented by:
Mohammad Al-Haddad, M.D.
Assistant Professor of Clinical Medicine
Indiana University School of Medicine
Division of Gastroenterology and Hepatology
550 University Boulevard
Indianapolis, IN 46202-5149
Introduction
The introduction of the curved linear array echoendoscope in the early 1990s created the opportunity
for endoscopic ultrasound fine needle aspiration (EUS-FNA). Since that time, FNA has been the main
driving force behind the growth of EUS and the vast expansion of its applications. This includes
sampling of a variety of pathological conditions, including gastrointestinal and extra gastrointestinal
Mohammad Al-Haddad, M.D.
masses, cysts, and lymphadenopathy. The availability of FNA devices of various sizes, and the more
Assistant Professor of Clinical Medicine
Indiana University School of Medicine
Division of Gastroenterology and Hepatology
550 University Boulevard
Indianapolis, IN 46202-5149
recent introduction of core biopsy devices helped improve tissue yield and allowed sampling of most
lesions within the reach of any echoendoscope. The high diagnostic accuracy of EUS-FNA and its
excellent safety profile facilitated its widespread adoption in most hospitals and cancer centers. This
paper aims at introducing the proper technique for EUS guided tissue sampling and highlights the
related aspects of cytological and histological processing.
sampling TECHNIQUEs
Basic EUS-guided Sampling Technique
Endoscopic ultrasound guided fine needle aspiration (EUS-FNA) is a valuable and safe tool to obtain cellular material for cytological examination.1,2
The advent of EUS accessories like core biopsy devices facilitated obtaining histological materials from solid lesions. In experienced hands, EUS-FNA
or core biopsy of lesions and lymph nodes above and below the diaphragm has been demonstrated to be extremely safe when compared with other
tissue sampling modalities, with a risk profile similar to that of conventional endoscopy.3
EUS guided tissue acquisition starts by appropriately identifying the lesion of interest and its characteristics including shape, size, and relationship
to surrounding structures. The lesion is then interrogated using the linear array echoendoscope to determine an appropriate puncture site. The
ultrasound transducer on the distal tip of the echoendoscope permits needle advancement into the lesion under real-time guidance. EUS-FNA and
core biopsies are performed after Doppler assessment to avoid puncturing intervening blood vessels.4
Once the gut wall is punctured and the needle enters the target lesion, the stylet is withdrawn. Whether or not to apply suction during FNA remains
controversial but should be tailored to the specimen’s volume and the amount of blood noted on the first pass performed with suction. The needle is
then moved back and forth through the lesion for at least 30 seconds or until deemed adequate by the endosonographer. The needle is then withdrawn
back into the sheath, the assembly is removed, and the sample is processed per institutional protocol.
Cytology
This refers to the science of cell interpretation, and is the basic and most common pathology
preparation technique used to process the material obtained in the vast majority of EUS
procedures. Cytological specimens obtained during EUS-FNA consist mainly of “loose” cells or
small groups of cohesive cells rather than “cores” of tissue. Cytology interpretation has evolved as
an independent sub-specialty in pathology serving EUS and other image-guided tissue acquisition.
Cytology preparation starts in the GI lab soon after the FNA is performed.
The target lesion is first identified under EUS guidance and then punctured using the standard
19, 22 or 25 gauge* FNA needle as described above.4 The material retrieved from aspiration is
then expressed onto a set of two glass slides (referred to as smears). The first slide is air-dried
(or placed on a heated plate) for immediate staining and on-site review. The air dried specimens
are then dipped in the Diff Quick stain which is typically available in the GI lab (Figure 1) and are
ready for onsite cytological examination to determine adequacy of the specimen. In most referral
institutions, rapid onsite evaluation is available and has been shown to improve the diagnostic
yield and provides feedback to the endosonographer about quality and adequacy of the specimen
and the need of further passes to reach a diagnosis.5-7
2
Figure 1
Diff-quick stained slide from a lymph node prepared
in the GI lab and ready for rapid on-site cytological
review
sampling TECHNIQUEs – Continued
The other slide is sprayed with 95% ethyl alcohol and polyethylene glycol (Figure 2), followed by
Papanicolaou (Pap) staining later in the lab for more detailed cytologic exam (Figure 3). While in
the majority of cases, the final diagnosis (e.g. malignancy) is made based on the Diff Quick slides,
the Pap smears bring out nuclear details clearly, allowing better identification of malignant cells
when the quality of the Diff Quick slides is suboptimal. Therefore, the 2 preparation methods
complement each other and are routinely obtained on every pass. It is important to keep in
mind that the ability of cytologists and endosonographers to provide a final diagnosis on FNA
specimens also takes into account the clinical history of the patient and findings from EUS or
imaging studies.
What is a Cell-Block?
Cell blocks are prepared from residual material obtained from FNA after smears are prepared
and are useful adjuncts for establishing a more definitive cytopathological diagnosis. Although
cell blocks are almost routinely obtained during EUS-FNA using excess material after smear
preparation, they can be particularly useful for the diagnosis and classification of lesions that
otherwise may not be possible from smears only. In such cases, it is important to obtain at least
2 additional passes dedicated for cell block (i.e., no smears are prepared from these passes)
to ensure adequate material is provided. The specimens are typically submitted in a special
preservative solution, a commonly used one being RPMI-1640 (Roswell Park Memorial Institute
medium). The solution undergoes centrifugation in the lab to provide a pellet of solid material
(Figure 4). The pellet is then fixed in 10% Formalin, and subsequently embedded in paraffin,
sectioned in thin slices, and stained with H&E (hematoxylin and eosin – Figure 5) for further review
by the pathologist.
Figure 2
Alcohol-fixed slide from a lymph node prior to further
processing in the lab for Pap staining.
Figure 3
A Pap smear from a pancreatic cyst FNA
demonstrating mucinous epithelium. The degree of
nuclear detailing provided by Pap smears facilitates
the diagnosis.
Additional studies (like immunocytochemistry-ICC) can be performed easily on cell block. ICC
employs a wide battery of antibodies that bind to specific antigens on certain cells (like cancer
cells) and therefore help confirm the diagnosis if such cells are present within the cell block. ICC
on metastatic liver lesions and lymph nodes can also help further define what type of primary
cancer is suspected. If lymphoma is suspected, 2-3 dedicated passes from the lymph node(s) are
usually submitted in RPMI for flowcytomtery, a specialized test that may allow the identification of
monoclonal lymphocytes (lymphoma cells) based on specific surface antigens.
Histology
This concept refers to a different method of pathological processing and is the basic technique
used to examine the vast majority of specimens obtained during surgical resection (like removing
tumors) or endoscopy (e.g., removing polyps from the colon, or taking mucosal biopsies using
forceps). Also referred to as “Trucut” biopsies in EUS guided sampling, this method was developed
to process “pieces” or “cores” of tissue for histological examination, which are often difficult
to obtain during routine EUS-FNA, due to the very small caliber of the needles used, and the
dependence of the FNA needles on suction to acquire tissue.8-13 Therefore, specialized needle
core biopsy devices had to be developed for use in EUS to reliably provide cores that depend on
mechanical shearing to obtain tissue.
Figure 4
Cell block precipitates after centrifuging the tube. The
supernatant (red fluid on the right tube) is discarded
and the cell pellet (left tube) is retrieved for further
cytological processing.
The performance of an older generation spring-loaded EUS Trucut biopsy device was suboptimal
due to its stiffness, and difficulty to advance through the scope in angulated positions (like the
duodenum), leading to frequent mechanical failures. The tissue cores are typically visible to the
Figure 5
A paraffin block (middle) is used to embed
histology specimens (including cell pellets) prior
to being sectioned in thin slices, stained with H&E
(hematoxylin and eosin-slide on right) for further
review by the pathologist.
3
sampling TECHNIQUEs – Continued
naked eye and can range in size from a few to several millimeters in size (Figures 6 and 7). Recent
early clinical data using a 19 gauge needle (Expect 19 gauge Flex™, Boston Scientific) show
promise in providing adequate cores from solid lesions (Figures 6 and 7), but large scale studies
are needed to confirm this observation.14
Tissue obtained for histopathology is submitted to the lab in Formalin for standard histology
processing that later involves paraffin-embedding and staining with hematoxylin and eosin (H&E),
the most commonly used stain. If immediate cytology review is desired, touch preps can be
prepared by rolling the tissue core(s) onto a glass slide (prior to dropping it in Formalin), followed
by air drying it and staining it as routinely done. However, in most cases, no immediate cytology
review is performed, and no special preparation of the specimen is needed prior to sending it to
the lab.
Figure 6
Several visible cores obtained using the Expect™
19-gauge Flex Needle from a gastric subepithelial
lesion and placed in Formalin.
Lacking the ability to perform on site review to assess sample adequacy, core biopsy sampling
can sometimes be inadequate on its own to render a diagnosis. Indeed, many experts advocate
combining FNA with core biopsies to increase sample adequacy.15,16 Once core biopsies are
processed and deemed adequate, special staining using immunohistochemistry (IHC, which is
similar in concept to the immunocytochemistry discussed above) can be readily performed, if
needed, to confirm the diagnosis of certain tumors. The turnaround time for IHC on biopsies is
typically 7-10 days and varies from one laboratory to another.
Figure 7
Two visible cores from a gastric subepithelial lesion
obtained using the Expect 19-gauge Flex Needle
displayed temporarily on a glass slide prior to placing
in Formalin for histological processing.
Cytology vs. Histology
Cytology vs. Histology
During EUS, samples could be obtained for both cytology and histology if needed. The acquisition of histology samples in addition to cytology is
particularly helpful if rapid onsite interpretation is not available, or when preliminary onsite review indicates inadequate or non-diagnostic specimen.
In cytology, the presence of large amounts of blood, necrotic material or inflammatory cells can mask tumor cells leading to non-diagnostic specimen.
In addition, when certain conditions or diagnoses are suspected, the presence of a “core” of tissue could be important to provide a definitive diagnosis.
For example, histology, if obtainable, is favorable to cytology in sampling enlarged lymph nodes (to rule out lymphoma) or the liver (when cirrhosis
is suspected), where tissue architecture is important to study. In submucosal lesions17,18 (like gastrointestinal stromal tumors) and autoimmune
pancreatitis,19 histology allows for special staining (immunohistochemistry) that provides accurate diagnosis. Nevertheless, obtaining core biopsies
during EUS is not always feasible due to the large size of the biopsy device (typically 19-gauge needle), location and size of the lesion, and the need for
operator expertise. Therefore, a core biopsy device that is consistently able to access lesions in various locations and provide adequate histological
samples is much needed.
Molecular (DNA) Analysis
This is available in many referral hospitals as well as a central commercial lab (RedPath®, Pittsburgh, PA). This test is commonly used in pancreatic
cysts, but could be used in other pancreatic and biliary cancers.20 In the case of pancreatic cysts, a small portion of the pancreatic cyst fluid (usually
200 mcg) is analyzed for common mutations (like K-ras point mutations) that could accurately categorize the pancreatic cyst as mucinous or nonmucinous, and potentially identify the malignant cysts in an early stage. Mucinous cysts are considered premalignant and, therefore, should be
surveyed periodically by imaging or surgically removed when appropriate. Material to be sent for this analysis is submitted separately but, typically, in
addition to routine cytology and other tumor markers from the cyst fluid. The same test recently became commercially available to help differentiate
benign from malignant pancreatic masses when standard cytology is non-diagnostic.
4
EUS-fna Sample preparation Summary
Cytology
What is it?
How to Perform?
When to use it ?
Cytology obtained during EUS-FNA
consist mainly of “loose” cells or
small groups of cells
Obtained during EUS-FNA using
a standard 19, 22 and 25 gauge
FNA needles. Specimens can be
air dried for immediate on-site
review and/or alcohol fixed for later
Pap staining and interpretation.
Cell block can be performed by
submitting additional passes in cell
preservative for later processing
and special staining. It is possible
that larger size (like 19 gauge)
needles could provide maximal
amounts of tissue in fewer passes.
The majority of aspirates obtained
during EUS are processed as
cytological specimens and are
important for the diagnosis of tumors,
cysts, lymph nodes and other lesions
examined by EUS
What is it?
How to Perform?
When to use it ?
Cores of tissue obtained provide
more abundant material than
cytology but requires larger caliber
and more specialized needles
Tissue is acquired similar to the
FNA process. Specimens are
submitted in Formalin and sent
directly to the pathology lab
Adjunct to cytology to establish
diagnosis when:
Histology
1.FNA is non-diagnostic or inadequate
2.Tissue architecture is needed (e.g.
lymphoma, chronic liver disease,
auto-immune pancreatitis – AIP)
3.Special stains (immunohistochemistry)
are needed (e.g. gastrointestinal
stromal tumors – GIST)
Molecular Analysis
What is it?
How to Perform?
When to use it ?
DNA analysis of common genetic
mutations in the specimen
Standard FNA needles are used to
sample pancreatic cysts or masses
Helps accurately identify malignant
and premalignant pancreas cysts, and
assists in differentiate benign from
malignant pancreatic masses
5
Case 1: eus-fna for gist diagnosis
Introduction
A 46-year-old female patient with no known history of gastrointestinal illness presented to the local emergency room with one week history of melena
and generalized weakness. On physical exam she was found to have conjunctival pallor and epigastric tenderness. On laboratory tests her hemoglobin
was 6.5 mg/dl. She admitted to the hospital for blood transfusion and investigation of her suspected gastrointestinal bleeding.
Evaluation and Management
The patient was initiated on intravenous proton pump inhibitor therapy and transfused with 3 units of packed red blood cells. Upper endoscopy was
performed within 12 hours of admission and revealed a 3.5 cm ulcerated subepithelial mass in the proximal gastric body. Two distinct ulcers were
noted on the surface of the lesion, one of which exhibited a visible vessel, seen after flushing an adherent clot (Figure 1). This ulcer was deemed to be
the source of the recent gastrointestinal bleeding and was injected with epinephrine and treated with bipolar cautery. The patient showed no signs of
continued bleeding and was discharged home in 48 hours in a stable condition on oral proton pump inhibitor agent.
Endoscopic ultrasound (EUS) was performed one week after discharge from the hospital and confirmed the presence of the gastric mass. After
complete submersion under water, the lesion was carefully interrogated and was found to be hypoechoic and homogenous, originating from the fourth
wall layer (muscularis propria). Fine needle aspiration was performed using the 19 gauge Expect™ Flex Needle (Figure 2). Rapid on-site cytological
review of the first pass revealed clusters of spindle cells, and 2 subsequent passes were then directly submitted for cell block for immunocytochemistry.
To ensure specimen adequacy for special staining, 2 additional passes where performed and submitted in formalin for histological exam and
immunohistochemistry. Several small cores were visible, ranging in size from 2-4 mm. Final cytological and histological examination confirmed the
diagnosis of GIST (Figure 3 - core biopsy, hematoxylin and eosin stain), where both immunocytochemistry and immunohistochemistry demonstrated
positive staining for c-kit (CD 117 - Figure 4). The patient was referred for surgical resection.
Learning Points and Discussion
Obtaining samples with adequate cellularity from intramural lesions can be difficult during EUS-FNA due to the extreme mobility of those lesions. It is
important to keep the echoendoscope in a stable position and perform quick but precise movements while the lesion is punctured initially and during
the back and fro cycles. In this case, the use of large caliber needle (Expect 19-gauge Flex Needle) facilitated the diagnosis by providing highly cellular
passes with a relatively limited number of passes. When a stromal tumor is suspected, it is helpful to perform a core biopsy which supplements the
cytological diagnosis from FNA and help confirm the diagnosis by allowing immunohistochemical stains. In this case, the Expect 19-gauge Flex Needle
was able to provide adequate cytological material and good quality core biopsies.
6
Figure 1
Figure 2
Figure 3
Figure 4
Case 2: eus-fna for diagnosis of pancreatic head mass
Introduction
A 62-year-old male patient presented with a 2-month history of unexplained weight loss of 20 lbs. and a 1 week history of pruritus. He was admitted to
the hospital after his primary care physician detected jaundice on physical exam. Routine laboratory work revealed total bilirubin of 5.8 mg/dl. A CT
scan of the abdomen with intravenous contrast revealed a solid pancreatic head mass (Figure 1) with dilation of both the bile duct and pancreatic duct
upstream from the mass. The patient was referred to endoscopic ultrasound (EUS) for biopsy and staging of the pancreatic mass.
Evaluation and Management
Endoscopic ultrasound was performed and confirmed the presence of a 3.3 cm solid hypoechoic pancreatic head mass partially encasing the superior
mesenteric vein (Figure 2). The mass was visible from the duodenal bulb. Fine needle aspiration (FNA) was performed using the Expect™ 19-gauge Flex
Needle. On-site cytological review of the first pass revealed pleomorphic, overlapping cells with an increased nuclear-to-cytoplasmic ratio consistent
with adenocarcinoma (Figure 3, Diff Quick stain). Two additional passes were subsequently submitted directly for cell block analysis. Final cytological
interpretation confirmed the diagnosis of pancreatic adenocarcinoma. The patient was referred to a pancreatic surgeon.
Learning Points and Discussion
FNA of pancreatic head and uncinate lesions has traditionally been performed using either 22 or 25 gauge needles. The use of traditional 19 gauge
needles for sampling of such lesions was technically challenging. This was related to the angulation of the tip of the echoendoscope, typically located
in the first or second parts of the duodenum, prohibiting the advancement of 19 gauge needles through the scope and into the lesion of interest. The
advent of the Expect 19-gauge Flex Needle expanded the potential applications of 19 gauge needles to include sampling pancreatic head lesions.
Additional advantages of the needle include adequate cytological sampling in potentially fewer passes, and ability to provide histological specimens
(core biopsies) if needed. This needle can be considered as a first line needle or when smaller needles fail to provide the diagnosis when sampling
pancreatic head lesions.
Figure 1
Figure 2
Figure 3
7
References
1. Vilmann P, Jacobsen GK, Henriksen FW, Hancke S. Endoscopic
ultrasonography with guided fine needle aspiration biopsy in pancreatic
disease. Gastrointestinal Endoscopy. 1992;38(2):172-3.
2. Erickson RA. EUS-guided FNA. Gastrointestinal Endoscopy. 2004;60(2):267-79.
3. Al-Haddad M, Wallace MB, Woodward TA, Gross SA, Hodgens CM, Toton RD,
et al. The safety of fine-needle aspiration guided by endoscopic ultrasound: a
prospective study. Endoscopy. 2008;40(3):204-8.
4. Technology Assessment Status Evaluation: tissue sampling during
endosonography. February 1997. ASGE. American Society for Gastrointestinal
Endoscopy. Gastrointestinal Endoscopy. 1998;47(6):576-8.
5. Hikichi T, Irisawa A, Bhutani MS, Takagi T, Shibukawa G, Yamamoto G, et
al. Endoscopic ultrasound-guided fine-needle aspiration of solid pancreatic
masses with rapid on-site cytological evaluation by endosonographers
without attendance of cytopathologists. Journal of Gastroenterology.
2009;44(4):322-8.
6. LeBlanc JK, Emerson RE, Dewitt J, Symms M, Cramer HM, McHenry L,
et al. A prospective study comparing rapid assessment of smears and
ThinPrep for endoscopic ultrasound-guided fine-needle aspirates. Endoscopy.
2010;42(5):389-94.
7. Klapman JB, Logrono R, Dye CE, Waxman I. Clinical impact of on-site
cytopathology interpretation on endoscopic ultrasound-guided fine needle
aspiration. The American Journal of Gastroenterology. 2003;98(6):1289-94.
8. Varadarajulu S, Fraig M, Schmulewitz N, Roberts S, Wildi S, Hawes RH, et al.
Comparison of EUS-guided 19-gauge Trucut needle biopsy with EUS-guided
fine-needle aspiration. Endoscopy. 2004;36(5):397-401.
9. Gines A, Wiersema MJ, Clain JE, Pochron NL, Rajan E, Levy MJ. Prospective
study of a Trucut needle for performing EUS-guided biopsy with EUS-guided
FNA rescue. Gastrointestinal Endoscopy. 2005;62(4):597-601.
10. Levy MJ, Wiersema MJ. EUS-guided Trucut biopsy. Gastrointestinal
Endoscopy. 2005;62(3):417-26.
11. Storch I, Jorda M, Thurer R, Raez L, Rocha-Lima C, Vernon S, et al. Advantage
of EUS Trucut biopsy combined with fine-needle aspiration without
immediate on-site cytopathologic examination. Gastrointestinal Endoscopy.
2006;64(4):505-11.
12. Aithal GP, Anagnostopoulos GK, Tam W, Dean J, Zaitoun A, Kocjan G, et
al. EUS-guided tissue sampling: comparison of “dual sampling” (Trucut
biopsy plus FNA) with “sequential sampling” (Trucut biopsy and then FNA as
required). Endoscopy. 2007;39(8):725-30.
13. Adler DG, Conway JD, Coffie JM, Disario JA, Mishkin DS, Shah RJ, et al. EUS
accessories. Gastrointestinal Endoscopy. 2007;66(6):1076-81.
14. Al-Haddad M et al. Early Clinical Experience with a new EUS-guided 19-gauge
Flexible Fine Needle Aspiration (FNA) Device: A Multicenter Study. Accepted
for oral presentation, Digestive Disease Week, 2012.
15. Larghi A, Verna EC, Ricci R, Seerden TC, Galasso D, Carnuccio A, et al.
EUS-guided fine-needle tissue acquisition by using a 19-gauge needle in a
selected patient population: a prospective study. Gastrointestinal Endoscopy.
2011;74(3):504-10.
16. Wittmann J, Kocjan G, Sgouros SN, Deheragoda M, Pereira SP. Endoscopic
ultrasound-guided tissue sampling by combined fine needle aspiration and
trucut needle biopsy: a prospective study. Cytopathology: Official Journal of
the British Society for Clinical Cytology. 2006;17(1):27-33.
17. Thomas T, Kaye PV, Ragunath K, Aithal G. Efficacy, safety, and predictive
factors for a positive yield of EUS-guided Trucut biopsy: a large tertiary
referral center experience. The American Journal of Gastroenterology.
2009;104(3):584-91.
18. Lee JH, Choi KD, Kim MY, Choi KS, Kim do H, Park YS, et al. Clinical impact
of EUS-guided Trucut biopsy results on decision making for patients with
gastric subepithelial tumors >/= 2 cm in diameter. Gastrointestinal Endoscopy.
2011;74(5):1010-8.
19. Mizuno N, Bhatia V, Hosoda W, Sawaki A, Hoki N, Hara K, et al.
Histological diagnosis of autoimmune pancreatitis using EUS-guided trucut
biopsy: a comparison study with EUS-FNA. Journal of Gastroenterology.
2009;44(7):742-50.
20. Khalid A, Zahid M, Finkelstein SD, LeBlanc JK, Kaushik N, Ahmad N, et al.
Pancreatic cyst fluid DNA analysis in evaluating pancreatic cysts: a report of
the PANDA study. Gastrointestinal Endoscopy. 2009;69(6):1095-102.
Boston Scientific Corporation
One Boston Scientific Place
Natick, MA 01760-1537
www.bostonscientific.com/endoscopy
www.youtube.com/BostonScientificEndo
*SI unit conversion: 19 gauge needle = .040"; 22 gauge needle = .028"; 25 gauge needle = .020"
Results from case studies are not predictive of results in other cases. Results in other cases may vary.
Expect is an unregistered trademark of Boston Scientific Corporation or its affiliates.
Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device.
Caution: Federal (USA) law restricts this device to sale by or on the order of a physician.
Ordering Information
1.800.225.3226
Distributed by permission of
Dr. Mohammad Al-Haddad, M.D.
ENDO-78108-AA April 2012